Atrial natriuretic peptide, a type of cardiac- and vascular-derived peptide hormone, has been proven to be a potential drug for CRC owing to its anti-proliferative effect via inhibition of the Wnt/β-catenin signaling cascade and increasing intracellular acidification [41]. This evidence concerns the gene NPPA and colorectal carcinoma.